- Home
- ARCT vs PCRX Comparison
ARCT vs PCRX Comparison
Compare ARCT & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCT
- PCRX
- Stock Information
- Founded
- ARCT 2013
- PCRX 2006
- Country
- ARCT United States
- PCRX United States
- Employees
- ARCT N/A
- PCRX N/A
- Industry
- ARCT Biotechnology: Pharmaceutical Preparations
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- ARCT Health Care
- PCRX Health Care
- Exchange
- ARCT Nasdaq
- PCRX Nasdaq
- Market Cap
- ARCT 320.8M
- PCRX 1.2B
- IPO Year
- ARCT N/A
- PCRX 2011
- Fundamental
- Price
- ARCT $18.05
- PCRX $26.07
- Analyst Decision
- ARCT Strong Buy
- PCRX Buy
- Analyst Count
- ARCT 10
- PCRX 6
- Target Price
- ARCT $50.88
- PCRX $30.00
- AVG Volume (30 Days)
- ARCT 493.8K
- PCRX 599.4K
- Earning Date
- ARCT 11-06-2025
- PCRX 11-05-2025
- Dividend Yield
- ARCT N/A
- PCRX N/A
- EPS Growth
- ARCT N/A
- PCRX N/A
- EPS
- ARCT N/A
- PCRX N/A
- Revenue
- ARCT $122,122,000.00
- PCRX $705,848,000.00
- Revenue This Year
- ARCT N/A
- PCRX $7.36
- Revenue Next Year
- ARCT $28.92
- PCRX $10.07
- P/E Ratio
- ARCT N/A
- PCRX N/A
- Revenue Growth
- ARCT N/A
- PCRX 2.25
- 52 Week Low
- ARCT $8.04
- PCRX $13.42
- 52 Week High
- ARCT $25.88
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- ARCT 58.87
- PCRX 51.80
- Support Level
- ARCT $16.54
- PCRX $26.22
- Resistance Level
- ARCT $19.50
- PCRX $27.50
- Average True Range (ATR)
- ARCT 1.08
- PCRX 0.93
- MACD
- ARCT -0.08
- PCRX -0.14
- Stochastic Oscillator
- ARCT 56.46
- PCRX 21.89
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.